Retroperitoneal non-functioning paraganglioma: A difficult tumour to diagnose and treat

Emma Gannan\textsuperscript{a, b, *}, Penelope van Veenendaal\textsuperscript{b}, Adam Scarlett\textsuperscript{c}, Michael Ng\textsuperscript{a}

\textsuperscript{a} Department of General Surgery, Ballarat Base Hospital, Drummond St North, Ballarat, VIC 3350, Australia
\textsuperscript{b} Department of General Surgery, The Royal Melbourne Hospital, Grattan St, Parkville, VIC 3050, Australia
\textsuperscript{c} Department of Pathology, Ballarat Base Hospital, Drummond St North, Ballarat, VIC 3350, Australia

\textbf{A R T I C L E   I N F O}

Article history:
Received 15 July 2015
Received in revised form 8 November 2015
Accepted 8 November 2015
Available online 12 November 2015

Keywords:
Paraganglioma
Organ of Zuckerkandl
Neuroendocrine tumour

\textbf{A B S T R A C T}

Paragangliomas are rare neoplasms arising from cells of the primitive neural crest. These tumours are often difficult to diagnose and treat. We report a case of a 42 year old female presenting with abdominal pain who had a retroperitoneal tumour situated at the aortic bifurcation. Serum catecholamine levels were normal. Complete resection of the tumour was performed. The histological examination and immunohistochemical analyses concluded the diagnosis of an organ of Zuckerkandl paraganglioma.

© 2015 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\textbf{1. Introduction}

Paragangliomas are rare neuroendocrine tumours arising from a widely dispersed collection of specialised neural crest cells [1]. The adrenal medullae represent the largest collection of paraganglion tissue; tumours derived from them occur much more frequently than in extra-adrenal locations. It has been estimated that 10% of paragangliomas arise outside the adrenal glands [2]. The most common site of extra-adrenal occurrence is intra-abdominal, usually within the para-aortic and peri-nephric spaces [3]. Other rarer sites include the thorax, skull base and neck. Paragangliomas may be functional and result in symptoms of excess catecholamine production. Approximately 10–15% of such tumours is non-functional, and in another 10% hormone activity is not manifest clinically. They are often locally invasive and associated with a high incidence of local recurrence [4].

Non-functional paragangliomas pose a significant diagnostic challenge. In the absence of typical symptoms of catecholamine excess, the diagnosis of such tumours is often delayed [5]. In this report, the authors describe a new case of non-functional retroperitoneal paraganglioma discovered during investigation of abdominal pain.

\textbf{2. Presentation of case}

A 42 year old female was referred with vague abdominal pain of several years duration. She had a history of hypertension and her blood pressure was 135/95 mmHg at the time of admission, however she denied symptoms of catecholamine excess. She was taking no regular medications. There was no family history of illness. The physical examination was unremarkable with no palpable abdominal mass present. Abdominal ultrasonography showed an abnormal soft tissue mass anterior to the aortic bifurcation, initially thought to represent lymphadenopathy. Abdominal computed tomography (CT) showed a solitary well-defined heterogeneous mass centred level with the L5 vertebra body slightly to the left of midline, immediately anterior to the two common iliac arteries (Fig. 1) which was more consistent with paraganglioma. CT chest showed no intrathoracic malignancy. Serum chromogranin A level was elevated at 276\textmu g/L (normal range 27–94\textmu g/L). The lesion was completely resected through a midline laparotomy incision. On macroscopic examination the mass measured 5.5 × 4.0 × 2.5 cm and was encapsulated with a lobulated, variegated orange/brown cut surface and central areas of hemorrhage (Fig. 2).

Histological examination identified a highly cellular, multinodular encapsulated tumour with a vascular framework containing many dilated and congested blood vessels (Fig. 3). The tumour was composed of compact nests of varying size in alveolar pattern. Two cell populations were noted within the tumour: larger epithelioid type cells with ill-defined granular cytoplasm and cells with small ovoid to polygonal monomorphic nuclei with granular chromatic pattern. The other cells were smaller, somewhat similar with scant cytoplasm. In places,zellballen pattern of paraganglioma was apparent. Diffuse sheets of tumour cells were also present. In

\textbf{Abbreviations:} CT, computed tomography; NSE, neuron-specific enolase; MIBG, metaiodobenzylguanidine.

* Corresponding author at: Department of General Surgery, The Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia.

E-mail address: egannan@yahoo.com.au (E. Gannan).

http://dx.doi.org/10.1016/j.ijscr.2015.11.004
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
one area, larger cells of epithelioid type, with eosinophilic granular cytoplasm, arranged in strands showed variation in nuclear size and shape with hyperchromasia. Occasional multinucleate giant cells were also seen. The tumour infiltrated the capsule and fibro-collagenous bands. Probable lymphovascular permeation was present. Immunohistochemical staining of the tumour showed that it strongly expressed chromogranin (Fig. 4), neuron-specific enolase (NSE) and synaptophysin. These findings led to a histological diagnosis of retroperitoneal paraganglioma.

Post-operative 24-hour urine catecholamine studies and plasma metanephrines were negative. Scintigraphy with 123-I labeled metaiodobenzylguanidine (MIBG) was also negative. There were no complications over 6 months of follow up.

3. Discussion

Paragangliomas are rare tumours arising from sympathetic and parasympathetic paraganglia, which are derived from the neural crest cells. Those arising from the adrenal medulla are named phaeochromocytoma and comprise approximately 80% of these tumours. Extra-adrenal paragangliomas are found arising from chromaffin tissue along the autonomic nervous system and can thus be found in the head, neck, thorax, abdomen and pelvis. The most common site of sympathetic paragangliomas is in the abdomen, usually located in the organ of Zuckerkandl at the aortic bifurcation, consistent with the distribution of paraganglia first characterized in the human fetus by Zuckerkandl in 1901 [6,7].

The median age of diagnosis for retroperitoneal paragangliomas is 37–43 years and the incidence is similar between men and women [1,8,9]. A large proportion of paragangliomas are related to disease-causing mutations or hereditary syndromes such as Von Hippel–Lindau (VHL) gene mutations, multiple endocrine neoplasia type 2 (MEN2), neurofibromatosis type 1 (NF1), the Carney triad and gene mutations of the subunits of succinate dehydrogenase (SDH) [10,11].

Patients with functional paragangliomas that produce catecholamines may experience hypertension, flushing, tachycardia, palpitations, anxiety, headache and/or profuse diaphoresis [4,5,12]. Those with non-functioning retroperitoneal paragangliomas may be diagnosed incidentally or present with compressive symptoms such as abdominal pain that may be associated with nausea, vomiting, abdominal distension and weight loss [4,13]. Non-functional retroperitoneal paragangliomas have also been reported to present atypically with chest pain or paralytic ileus [14,15]. The diverse range of presentations often makes the clinical diagnosis of these tumours difficult.
Serum levels of chromogranin A,NSE or vimentin are elevated with most of the neuroendocrine tumours and are helpful to differentiate them from non-neuroendocrine tumours. On the basis of endocrine symptoms, neuroendocrine tumours can be differentiated by using hormonal assay in blood or urine. Ultrasound may be used as a first-line investigation however CT and MRI have higher sensitivity. Paragangliomas may show central necrosis or haemorrhage, calcification and enhancement. Functional imaging with MIBG scintigraphy may be used for better localisation of extra-adrenal disease or metastatic sites. Angiography may be useful in revealing vascular invasion or in demonstrating small metastases [16]. Ultimately although imaging techniques are helpful, the diagnosis of paragangliomas can only be confirmed with careful histological and immunohistochemical evaluation [17,18].

Due to the malignant potential of paragangliomas, surgical excision is the preferred management. Resection is often challenging as these highly vascular tumours are frequently located near multiple vital blood vessels. If a tumour is felt to be unresectable, attempts to reduce its size using chemotherapy, radiation therapy or embolisation may be indicated because resection offers the only chance of cure [19]. Radiotherapy may also be used for inoperable tumours or for palliation. Radionucleotides may be the indicated therapy for tumours exhibiting uptake on diagnostic scan. Inoperable paragangliomas can be treated with octreotide [20].

Histologically paragangliomas are diagnosed by their highly vascular appearance, with chief cells and sustenacular cells arranged in clusters calledzellballen. Chief cells are often positive for neuroendocrine markers (synaptophysin, NSE, chromogranin) on immunohistochemistry, while sustenacular cells are positive for S-100 protein [5]. Malignancy cannot be reliably diagnosed histologically and is often diagnosed based on presence of metastases. Approximately 20–42% of extra-adrenal sympathetic paragangliomas metastasise, compared to only 2–10% of phaeochromocytomas. Sites of metastasis include lymph nodes, bone, liver and lung. Metastatic lesions have a poor prognosis, with a reported 5-year survival rate of 36% [4].

4. Conclusion

Paragangliomas of the retroperitoneum are a rare group of tumours with malignant potential that cause considerable difficulty both in diagnosis and treatment. Our case highlights the importance of including the extra-adrenal paraganglioma in the differential diagnosis of retroperitoneal tumours. Advances in genetic testing and discovery of new molecular markers are contributing to increased understanding of paragangliomas, however at present there is no way to definitively predict metastatic risk. As recurrence and metastasis are common, lifelong follow-up is required.

Consent

Written consent was obtained from the patient to publish this case report.

Conflict of interest

The authors report no conflict of interest.

Funding

None.

Ethical approval

None.

Author contribution

Emma Gannan: writing.
Penelope van Veenendaal: review and editing.
Adam Scarlett: pathological analysis.
Michael Ng: review.
All authors approved the final version of the manuscript to be submitted.

Guarantor

Mr Michael Ng.

References

[1] N. Feng, W.Y. Zhang, X.T. Wu, Clinicopathological analysis of paraganglioma with literature review, World J. Gastroenterol. 15 (June (24)) (2009) 3003–3009.
[2] J. Wen, H.Z. Li, Z.G. Ji, Q.Z. Mao, B.B. Shi, W.G. Yan, A case of large silent extra-adrenal retroperitoneal paraganglioma resected laparoscopically, Chin. Med. Sci. J. 25 (2010) 61–64.
[3] R.K. Whalen, A.F. Althausen, G.H. Daniels, Extra-adrenal pheochromocytoma, J. Urol. 147 (1992) 1–10.
[4] L.M. Scalfani, J.M. Woodruff, M.F. Brennan, Extraadrenal retroperitoneal paragangliomas: natural history and response to treatment, Surgery 108 (1990) 1124–1130.
[5] E.E. Lack, A.L. Cubilla, J.M. Woodruff, P.H. Lieberman, Extra-adrenal paragangliomas of the retroperitoneum: a clinicopathologic study of 12 tumours, Am. J. Surg. Pathol. 4 (1980) 109–120.
[6] R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng, Pathology and genetics of tumours of endocrine organs, in: World Health Organization Classification of Tumours, IARC Press, Lyon, France, 2004.
[7] E. Zuckerkandl, Ueber neoorgane des sympathicus in retroperitonealearium des menschen, Anat. Anz. 15 (1901) 91.
[8] P. Somasundar, R. Krouse, R. Hostetter, R. Vaughan, T. Covey, Paragangliomas: diagnosis of clinical experience, J. Surg. Onc. 74 (2000) 286–290.
[9] W.S. Hayes, A.J. Davidson, P.M. Grimaly, D.S. Hartman, Extraadrenal retroperitoneal paraganglioma: clinical, pathologic and ct findings, AJR 155 (1990) 1247–1250.
[10] M. Jafri, E.R. Maher, The genetics of pheochromocytoma: using clinical features to guide genetic testing, Eur. J. Endocrinol. 166 (2012) 151–158.
[11] L.T. Van Hulstheijn, O.M. Dekkers, F.J. Hees, J.W. Smit, E.P. Corssmit, Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis, J. Med. Gen. 49 (12) (2012) 768–776.
[12] D. Erickson, Y.C. Kudva, M.J. Ebersold, G.B. Thompson, C.S. Grant, J.A. Van Heerden, W.F. Young Jr., Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients, J. Clin. Endocrinol. Metab. 86 (2001) 5210–5216.
[13] G.A. Kaltas, G.M. Besser, A.B. Grossman, The diagnosis and medical management of advanced neuroendocrine tumors, Endocr. Rev. 25 (2004) 458–511.
[14] P. Brahmbhatt, P. Patel, A. Saleem, R. Narayan, M. Young, Retroperitoneal paraganglioma presenting as a chest pain: a case report, Case Rep. Oncol. Med. (2013) 1–4, Art ID 329472.
[15] W.C. Lin, H.Y. Wang, C.W. Chang, J.L. Lin, C.H. Tsai, Retroperitoneal paraganglioma manifesting as paralytic ileus: a case report, J. Med. Case Rep. 6 (158) (2012) 1–5.
[16] Y.D. Patel, I.T. Morehouse, Malignant paragangliomas of the retroperitoneum: value of computed tomography and angiography, Clin. Radiol. 35 (1984) 185–188.
[17] A.P. Van Gils, T.H. Falke, A.R. van Leulk, J.W. Arndt, M.P. Sandler, A.G. van der Mey, et al., MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas, Radiographics 11 (1991) 37–57.
[18] A. Sahidec, A. Sohiba, J.P. Monson, A.B. Grossman, S.L. Chew, R.H. Reznik, CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas), Eur. Radiol. 15 (2005) 85–92.
[19] R.L. Bryant, D.R. Stevenson, D.W. Hunton, et al., Primary malignant retroperitoneal tumors, Am. J. Surg. 144 (1982) 646–649.
[20] R.A. Mikhail, J.B. Moore, D.N. Reed Jr., et al., Malignant retroperitoneal paragangliomas, J. Surg. Oncol. 32 (1986) 32–36.

Open Access

This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.